



Prescription Opioid Addiction Treatment Study (POATS) Blending Initiative Product Resource List

Peer-Reviewed Journal Articles

Albright, J., Ciaverelli, R., Essex, A., Tkacz, J., Ruetsch. (2010). Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. *Journal of Addiction Medicine*, 4(4), 197-203.

Alford, D.P., LaBelle, C.T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J.H. (2011). Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. *Archives of Internal Medicine*, 17(5), 425-31.

Barnett, P., Rodgers, J. & Bloch, D. (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. *Addiction*, 96, 683-90.

Bohnert, A.S.B., Valenstein, M., Bair, M.J., Ganoczy, D., McCarthy, J.F., Ilgen, M.A., & Blow, F.C. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. *Journal of the American Medical Association*, 305(13), 1315-21.

Bryson, W.C., McConnell, K.J., Korthuis, P.T., & McCarty, D. (2011). Extended-release naltrexone for alcohol dependence: Persistence and healthcare costs and utilization. *The American Journal of Managed Care*, 17(8), S213-22.

Burns, L., Randall, D., Hall, W., Butler, T., Bell, J., and Degenhardt, L. (2009). Opioid agonist pharmacotherapy in new South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. *Journal of Addiction*, 104, 1363-72.

Comer, S.D., Sullivan, M.A., Vosburg, S.K., Manubay, J., Amass, L., Cooper, Z.D., Saccone, P., and Kleber, H.D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. *Journal of Addiction*, 105, 709-18.

Comer, S.D., Walker, E.A., & Collins, E.D. (2005). Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. *Journal of Psychopharmacology*, 181, 664-75.

Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010). Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. *British Medical Journal*, 34, 1-8.

Peer-Reviewed Journal Articles, continued

- Cunningham, C., Giovanniello, A., Sacajiu, G., Whitley, S., Mund, P., Beil, R., & Sohler, N. (2008). Buprenorphine treatment in an urban community health center: What to expect. *Journal of Family Medicine, 40*(7), 500-06.
- Damschroder, L.J., Aron, D.C., Keith, R.E., Kirsh, S.R., Alexander, J.A., and Lowery, J.C. (2009). Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implementation Science, 4*, 50.
- Damschroder, L.J., & Hagedorn, H.J. (2011). A guiding framework and approach for implementation research in substance use disorders treatment. *Psychology of Addictive Behaviors, 25*(2), 194-205.
- Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & McLaren, J. (2010). Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. *Journal of Addiction, 106*, 32-51.
- Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacology program over 20 years: Risk factors and lives saved. *Journal of Drug and Alcohol Dependence, 105*, 9-15.
- Denisco, R.C., Kenna, G.A., O'Neil, M.G., Kulich, R.J., Moore, P.A., Kane, W.T., Mehta, N.R., Hersh, E.V., & Katz, N.P. (2011). Prevention of prescription opioid abuse: The role of the dentist. *Journal of the American Dental Association, 142*(7), 800-10.
- Ducharme, L.J., & Abraham, A.J. (2008). State policy influence on the early diffusion of buprenorphine in community treatment programs. *Journal of Substance Abuse Treatment, Prevention, and Policy, 3*(17), 1-10.
- Ducharme, L.J., Knudsen, H.K., & Roman, P.M. (2006). Evidenced-based treatment for opiate-dependent clients: Availability, variation, and organizational correlates. *The American Journal of Drug and Alcohol Abuse, 32*, 696-576.
- Ducharme, L.J., & Roman, P.M. (2009). Opioid treatment programs in the Clinical Trials Network: Representiveness and buprenorphine adoption. *Journal of Substance Abuse Treatment, 37*, 90-4.
- Egan, J.E., Casadonte, P., Gartenmann, T., Martin, J., McCance-Katz, E.F., Netherland, J., Renner, J.A., Weiss, L., Saxon, A.J., & Fiellin, D.A. (2010). The Physician Clinical Support System-Buprenorphine (PCSS-B): A novel project to expand/improve buprenorphine treatment. *Journal of General Internal Medicine, 25*(9), 936-41.

Peer-Reviewed Journal Articles, continued

- Fiellin, D.A., Moore, B.A., Sullivan, L.E., Becker, W., pantaloon, M.V., Chawarski, M.C., Barry, D., T., O'Connor, P., Schottenfeld, R.S. (2008). Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. *The American Journal on Addictions, 17*, 116-20.
- Fiellin, D.A., Pantalon, M.V., Chawarski, M.C., Moore, B.A., Sullivan, L.E., O'Connor, P.G., & Schottenfield, R.S. (2006). Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. *New England Journal of Medicine, 355*, 365-74.
- Johnson, R.E., Fudula, P.J., & Payne, R. (2005). Buprenorphine: Considerations for pain management. *Journal of Pain and Symptom Management, 29*(3), 297-326.
- Kahan, M., Srivastava, A., Ordean, A., Cirone, S. (2011). Buprenorphine: New treatment of opioid addiction in primary care. *Journal of Canadian Family Medicine, 57*, 281-89.
- Knudsen, H.K., Abraham, A.J., Johnson, J.A., & Roman, P.M. (2009). Buprenorphine adoption in the national drug abuse treatment Clinical Trials Network. *Journal of Substance Abuse Treatment, 37*, 307-12.
- Knudsen, H.K., Ducharme, L.J., Roman, P.M., & Link, T. (2005). Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. *Journal of Substance Abuse Treatment, 29*, 95-106.
- Ling, W., Jacobs, P., Hillhouse, M., Hasson, A., Thomas, C., Freese, T., Sparenborg, S., McCarty, D., Weiss, R., Saxon, A., Cohen, A., Straus, M., Brigham, G., Liu, D., McLaughlin, P., Tai, B. (2010). From research to real world: Buprenorphine in the decade of the Clinical Trials Network. *Journal of Substance Abuse Treatment, 38*, S53-60.
- Magura, S., & Rosenblum, A. (2001). Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. *Mount Sinai Journal of Medicine, 68*(1), 62-74.
- Marchand, K., Oviedo-Joekes, E., Guh, D., Brissette, S., Marsh, D., and Schechter, M.T. (2011). Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency. *BMC Health Services, 11*, 174.
- Mark, T.L., Kranzler, H.R., Song, X. (2003). Understanding U.S. addiction physicians' low rate of naltrexone prescription. *Journal of Drug and Alcohol Dependence, 71*, 219-28.

Peer-Reviewed Journal Articles, continued

Mark, T.L., Montejano, L.B., Kranzler, H.R., Chalk, M., & Gastfriend, D.R. (2010). Comparison of healthcare utilization among patients treated with alcoholism medications. *The American Journal of Managed Care*, 16(12), 879-88.

Martino, S., Brigham, G.S., Higgins, C., Gallon, S., Freese, T.E., Albright, L.M., Hulse, E.G., Krom, L., Storti, S.A., Peri, H., Nugent, C.D., Pintello, D., Condon, T.P. Partnerships and pathways of dissemination: The national institute on drug abuse—Substance abuse and mental health services administrations blending initiative in the Clinical Trials Network. *Journal of Substance Abuse Treatment*, 36(1), 31-43.

Mendelson, J., Flower, K., Pletcher, M.J., & Galloway, G.P. (2008). Addiction to prescription opioids: Characteristics of the emerging epidemic and treatment with buprenorphine. *Journal of Experimental and Clinical Psychopharmacology*, 16(5), 435-41.

Moore, B.A., Fiellin, D.A., Barry, D.T., Sullivan, L.E., Chawarski, M.C., O'Connor, P.G., & Schottenfeld, R.S. (2007). Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. *Society of General Internal Medicine*, 22, 527-30.

Netherland, J., Botsko, M., Egan, J.E., Saxon, A.J., Cunningham, C.O., Finkelstein, R., Gourevitch, M.N., Renner, J.A., Sohler, N., Sullivan, L.E., Weiss, L., & Fiellin, D.A. (2009). Factors affecting willingness to provide buprenorphine treatment. *Journal of Substance Abuse Treatment*, 36(3), 244-51.

Price, A.M., Ilgen, M.A., & Bohnert, A.S.B. (2011). Prevalence and correlates of nonmedical use of prescription opioids in patients seen in a residential drug and alcohol treatment program. *Journal of Substance Abuse Treatment*, 41(2), 208-14.

Reynaud, M., Petit, G., Potard, D., & Courty, P. (1998). Six deaths linked to concomitant use of buprenorphine and benzodiazepines. *Addiction*, 93(9), 1385-92.

Rieckmann, T., Kovas, A.E., & Rutkowski, B.A. (2010). Adoption of medications in substance abuse treatment: Priorities and strategies of single state authorities. *Journal of Psychoactive Drugs, SARC Supplement 6*, 227-38.

Rieckmann, T., Daley, M., Fuller, B.E., Thomas, C.P., and McCarty, D. (2007). Client and counselor attitudes toward the use of medications for treatment of opioid dependence. *Journal of Substance Abuse Treatment*, 32(2), 207-15.

Roman, P.M., & Johnson, J.A. (2002). Adoption and implementation of new technologies in substance abuse treatment. *Journal of Substance Abuse Treatment*, 22, 211-18.

Peer-Reviewed Journal Articles, continued

- Strassels, S.A. (2009). Economic burden of prescription opioid misuse and abuse. *Journal of Managed Care Pharmacy, 15*(7), 556-62.
- Sullivan, L.E., Barry, D., Moore, B.A., Chawarski, M.C., Tetrault, J.M., Pantaloni, M.V., O'Connor, P.G., Schottenfeld, R.S., Fiellin, D. (2006). A trial of integrated buprenorphine/naloxone and HIV clinical care. *Journal of Clinical Infectious Diseases, 43*, 184-90.
- Tai, B., Straus, M.M., Liu, D., Sparenborg, S., Jackson, R., & McCarty, D. (2010). The first decade of the National Drug Abuse Treatment clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. *Journal of Substance Abuse Treatment, 38*(1), 4-13.
- Thomas, C.P., Reif, S., Haq, S., Wallack, S.S., Hoyt, A., & Ritter, G.A. (2008). Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. *Journal of Psychiatric Services, 59*(8), 909-16.
- Upadhyay, J., Maleki, N., Potter, J., Elman, I., Rudrauf, D., Knudsen, J., Wallin, D., Pendse, G., McDonald, L., Griffin, M., Anderson, J., Nutile, L., Renshaw, P., Weiss, R., Becerra, L., & Borsook, D. (2010). Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. *Brain, 133*, 2098-114.
- Wallack, S.S., Thomas, C.P., Martin, T.C., Chilingirian, & Reif, S. (2010). Substance abuse treatment organization as mediators of social policy slowing the adoption of a congressionally approved medication. *Journal of Behavioral Health Services and Research, 37*(1), 65-78.
- Weiss, R.D., Sharpe Potter, J., Fiellin, D.A., Byrne, M., Connery, H.S., Dickinson, W., Gardin, J., Griffin, M.L., Gourvetich, M.N., Haller, D.L., Hasson, A.L., Huang, Z., Jacobs, P., Kosinski, A.S., Lindblad, R., McCance-Katz, E.F., Provost, S.E., Selzer, J., Somoza, E.C., Sonne, S.C., & Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry, 68*(12), 1238-46.
- Weiss, R.D., Sharpe Potter, J., Provost, S.E., Huang, Z., Jacobs, P., Hasson, A., Lindblad, R., Smith Connery, H., Prather, K., & Ling, W. (2010). A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology. *Contemporary Clinical Trials, 31*(2), 189-99.
- West, J.C., Thomas, R., Kosten, M.D., Wilk, J., Svikis, D., Triffleman, E., Rae, D.S., Narrow, W.E., Duffy, F.F., & Regier, D.A. (2004). Challenges in increasing access to buprenorphine treatment for opiate addiction. *The American Journal on Addictions, 13*(1), 8-16.

Peer-Reviewed Journal Articles, continued

- Wu, L-T., Pilowsky, D.J., & Patkar, A.A. (2008). Non-prescribed use of pain relievers among adolescents in the United States. *Journal of Drug and Alcohol Dependence, 94*, 1-11.
- Wu, L-T., Rignwalt, C.L., Yang, C., Reeve, B.B., Pan, J-J., & Blazer, D.G. (2009). Construct and differential item functioning in the assessment of prescription opioid use disorders among American adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry, 48*(5), 563-72.
- Wu, L-T., Ling, W., Burchett, B., Blazer, D.G., Yang, C., Pan, J-J., Reeve, B.B., & Woody, G.E. (2011). Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. *Journal of Drug and Alcohol Dependence*. [ARTICLE IN PRESS]
- Wu, L-T., Woody, G.E., Yang, C., & Blazer, D.G. (2011). How do prescription opioid users differ from users of heroin of other drugs in psychopathology: Results from the national epidemiologic survey on alcohol and related conditions. *Journal of Addiction Medicine, 5*(1), 28-35.
- Wu, L-T., Woody, G.E., Yang, C., & Blazer, D.G. (2010). Subtypes of nonmedical opioid users: Results from the national epidemiologic survey on alcohol and related conditions. *Journal of Drug and Alcohol Dependence, 112*, 69-80.
- Wu, L-T., Woody, G.E., Yang, C., Mannelli, P., & Blazer, D.G. (2011). Differences in onset and abuse/dependence between prescription opioids and heroin: Results from the national epidemiologic survey on alcohol and related conditions. *Journal of Substance Abuse and Rehabilitation, 2*, 77-88.
- Wu, L-T., Woody, G.E., Yang, C., Pan, J-J., & Blazer, D.G. (2011). Abuse and dependence on prescription opioids in adults: A mixture categorical and dimensional approach to diagnostic classification. *Journal of Psychological Medicine, 41*, 653-64.

Research Reports, Treatment Manuals, and Ancillary Materials

- Center for Substance Abuse Treatment. (2005). *Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs, Treatment Improvement Protocol (TIP) Series 43*, DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, retrieved from <http://www.ncbi.nlm.nih.gov/books/NBK14677/>.

Research Reports, Treatment Manuals, and Ancillary Materials, continued

Center for Substance Abuse Treatment. (2004). *Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, Treatment Improvement Protocol (TIP) Series 40*, DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, retrieved from http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf.

Fiellin, D.A., Pantalon, M.V., Schottenfeld, R.S., Gordon, L., & O'Connor, P.G. (1999). *Manual for Standard Medical Management of Opioid Dependence with Buprenorphine*. West Haven, CT: Yale University School of Medicine, Primary Care Center and Substance Abuse Center, and West Haven VA/CT Healthcare System.

Institute of Medicine of the National Academies. (2011). *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research*. Washington, D.C.: Author.

Ling, W., & Obert, J. (n.d.). *Handbook for Recovery from Opiate Dependence*. Bethesda, MD: National Institute on Drug Abuse, Center for Clinical Trials Network.

National Association on Alcohol Abuse and Alcoholism (NIAAA). (2007). *Helping Patients Who Drink Too Much: A Clinician's Guide*. NIH Publication No. 07-3769. Bethesda, MD: U.S. Department of Health and Human Sciences, National Institute on Alcohol Abuse and Alcoholism.

World Health Organization. (2009). *Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence*. Geneva, Switzerland: Author.

Technical Reports, Fact Sheets, and Additional Data Sources

Centers for Disease Control and Prevention. (2002). IDU/HIV Prevention: Substance Abuse Treatment for Injection Drug Users – A Strategy with Many Benefits. Atlanta, GA: Author, retrieved from <http://www.cdc.gov/idu/facts/TreatmentFin.pdf>.

Centers for Disease Control and Prevention, National Center for HIV, STD and TB Prevention. (2000). *Methadone Maintenance Treatment*. Atlanta, GA: Author, retrieved from www.cdc.gov/idu/facts/MethadoneFin.pdf.

CESAR (2011a). Buprenorphine Treatment for Opioid Dependence. *Volume 20, Issue 22*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-22.pdf>.

CESAR (2011b). U.S. Retail Distribution of Buprenorphine Approaches 1.5 Million Grams. *Volume 20, Issue 23*. Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-23.pdf>.

Technical Reports, Fact Sheets, and Additional Data Sources, continued

CESAR (2011c). Number of Law Enforcement-Seized Buprenorphine Items Analyzed by U.S. Labs Increases Dramatically. *Volume 20, Issue 24*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-24.pdf>.

CESAR (2011d). Number of U.S. Emergency Department Visits Related to the Nonmedical Use of Buprenorphine More than Triples since 2006. *Volume 20, Issue 25*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-25.pdf>.

CESAR (2011e). Sixty-One Percent (61%) of Buprenorphine-Related Emergency Department Visits for Nonmedical Use. *Volume 20, Issue 26*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-26.pdf>.

CESAR (2011f). Buprenorphine Availability, Diversion, and Misuse: A Summary of the CESAR Fax Series. *Volume 20, Issue 34*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-34.pdf>.

CESAR (2011g). Clinical Trial Finds that While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use among Those Dependent on Prescription Opioids, 91% were Not Opioid Free at Follow-Up. *Volume 20, Issue 46*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-46.pdf>.

Substance Abuse and Mental Health Services Administration. (2001). *Federal Register: 42 CFR Part 8, Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction, Final Rule*. Rockville, MD: U.S. Department of Health and Human Services, retrieved from <http://dpt.samhsa.gov/pdf/regs.pdf>.

Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. (2009). Emerging Issues in the Use of Methadone, HHS Publication No. (SMA) 09-4368. *Substance Abuse Treatment Advisory, Volume 8, Issue 1*. Rockville, MD: U.S. Department of Health and Human Services, retrieved from <http://kap.samhsa.gov/products/manuals/advisory/pdfs/Methadone-Advisory.pdf>.

Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Division of Pharmacologic Therapies. (2007). *Summary Report of the Meeting: Methadone Mortality – A Reassessment*. Rockville, MD: U.S. Department of Health and Human Services, retrieved from http://dpt.samhsa.gov/pdf/Methadone_Report_10%2018%2007_Brief%20w%20attch.pdf.

Technical Reports, Fact Sheets, and Additional Data Sources, continued

Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Division of Pharmacologic Therapies. (n.d.). *Accreditation of Methadone Maintenance Treatment: Assuring Quality of Care*, retrieved from <http://dpt.samhsa.gov/pdf/001218accred.pdf>.

Vimont, C. (2011). Challenges of treating chronic pain in people with opioid dependence. Join Together Online, retrieved from, <http://www.drugfree.org/join-together/addiction/challenges-of-treating-chronic-pain-in-people-with-opioid-dependence> (June 24, 2011).

Websites

Addiction Technology Transfer Center Network: <http://www.attcnetwork.org>

Alliance of States with Prescription Monitoring Programs: <http://www.pmpalliance.org>

Buprenorphine Physician and Treatment Program Locator:
http://buprenorphine.samhsa.gov/bwns_locator/

How to Use Methadone Safely Campaign: <http://dpt.samhsa.gov/methadonesafety/index.aspx>

NIDA/SAMHSA Blending Initiative Website: www.nida.nih.gov/blending

PMP Center of Excellence, Brandeis University, Schneider Institutes for Health Policy:
<http://www.pmpexcellence.org>

SAMHSA-CSAT's Medication Assisted Treatment for Substance Use Disorders, Division of Pharmacologic Therapies: <http://dpt.samhsa.gov/medications/methadone.aspx>

SAMHSA-CSAT's Medication Assisted Treatment for Substance Use Disorders, Division of Pharmacologic Therapies, Opioid Treatment Program Accreditation:
<http://dpt.samhsa.gov/regulations/accreditation.aspx>